• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Reducing the side effects of chemotherapy

Bioengineer by Bioengineer
January 18, 2024
in Chemistry
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Dreaded side effects

Portrait of Dr. Johannes Karges

Credit: © RUB, Marquard

Dreaded side effects

Approximately half of all chemotherapy drugs used to treat cancer are platinum-based. They act against tumor cells, but they also do damage healthy body cells. This is what causes the dreaded side effects such as nausea, hair loss, liver and kidney damage.

Johannes Karges applies double selectivity in his research: The cell-damaging active substances are packaged in nanoparticles that are not harmful to the body. Moreover, they’re marked in such a way that they accumulate primarily in tumor cells. “They dock onto a specific receptor that is found to be overexpressed in cancer cells,” explains Karges. And they only develop their cell-damaging effect once they’ve been activated. The researchers use light for this purpose. “Ideally, it will no longer be necessary to perform surgery to treat a tumor,” as Johannes Karges outlines his vision. “We’ll administer the drug into the patient’s vein, wait until it has accumulated in the tumor and then position the patient under a red light lamp that specifically activates the compound and triggers the therapeutic effect.” The researchers successfully demonstrated this therapeutic concept in breast cancer cells and in mouse models with a breast cancer tumor. Thanks to the double selectivity of the newly developed active substances, none of the typical side effects were observed in the animal model. The breast cancer tumor, however, was selectively removed in a single treatment.

About the person

Johannes Karges (born in 1992) studied chemistry at the Philipps University Marburg. After completing his bachelor’s degree, he pursued postgraduate studies at Imperial College London on an Erasmus scholarship and obtained his master’s degree in Marburg in 2016. Karges then moved to Paris to write his doctoral thesis in medicinal inorganic chemistry under the supervision of Professor Gilles Gasser at the University of Paris Sciences & Lettres. He completed some of the research for this thesis in the laboratory of Professor Hui Chao at Sun Yat-Sen University (China).

In 2020, after successfully completing his doctorate, Karges joined the group of Professor Seth M. Cohen at the University of California San Diego. In 2022, he received a Liebig Fellowship from the Fonds der Chemischen Industrie, which enabled him to return to Germany and pursue a career as an independent researcher. He used this funding to set up his own research group at the Faculty of Chemistry and Biochemistry at Ruhr University. The group specializes in the interface between inorganic and medicinal chemistry.

Original publications

Huiling Zhou, Dongsheng Tang, Yingjie Yu, Lingpu Zhang, Bin Wang, Johannes Karges, Haihua Xiao: Theranostic Imaging and Multimodal Photodynamic Therapy and Immunotherapy using the mTOR Signaling Pathway, Nature Communications, 2023, DOI: 10.1038/s41467-023-40826-5

Dengshuai Wei, Yun Huang, Bin Wang, Lili Ma, Johannes Karges, Haihua Xiao: Photo-Reduction with NIR Light of Nucleus Targeting Pt(IV) Nanoparticles for Combined Tumor-Targeted Chemotherapy and Photodynamic Immunotherapy, Angewandte Chemie International Edition 2022, DOI: 10.1002/anie.202201486



Share12Tweet8Share2ShareShareShare2

Related Posts

blank

First-ever observation of the transverse Thomson effect unveiled

August 23, 2025
blank

Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

August 23, 2025

New Molecular-Merged Hypergraph Neural Network Enhances Explainable Predictions of Solvation Gibbs Free Energy

August 22, 2025

Shaping the Future of Dysphagia Diets Through 3D Printing Innovations

August 22, 2025

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    125 shares
    Share 50 Tweet 31
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Long Non-Coding RNAs in Hormone-Driven Cancers

Plants and Sound: Allies or Adversaries?

Residual Inflammation’s Impact on CKM Syndrome in Diabetes

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.